Regeneron Pharmaceuticals | REGN - Sales Revenues

Stock Price
755.37
Daily Change
13.92 1.88%
Monthly
-1.03%
Yearly
13.27%
Q1 Forecast
718.61

Regeneron Pharmaceuticals reported $3.88B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15.78B 360M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.56B 380M Sep/2025
Astellas Pharma JPY 524.32B 18.53B Sep/2025
AstraZeneca USD 15.19B 733M Sep/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.2B 70M Sep/2025
Eli Lilly USD 17.6B 2.04B Sep/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.55B 557M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Kyowa Hakko Kirin JPY 118.8B 7.13B Sep/2025
Merck USD 17.28B 1.47B Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 16.7B 2B Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
United Therapeutics USD 799.5M 900K Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025